Alkem Laboratories Limited

rs,

m 05 th August, 2022 The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Excha

₹ 25,764 million

umbai today. Key highlights of Q1FY23 financial performance  Total Revenue from Operations was ₹ 25,764 million, year-on-year decline of 5.7% India sales were ₹ 17,815 million, year-on-year decline of 6.7% Int

5.7%

nancial performance  Total Revenue from Operations was ₹ 25,764 million, year-on-year decline of 5.7% India sales were ₹ 17,815 million, year-on-year decline of 6.7% International sales were ₹ 7,604

₹ 17,815 million

Total Revenue from Operations was ₹ 25,764 million, year-on-year decline of 5.7% India sales were ₹ 17,815 million, year-on-year decline of 6.7% International sales were ₹ 7,604 million, year-on-year decline of 3.

6.7%

4 million, year-on-year decline of 5.7% India sales were ₹ 17,815 million, year-on-year decline of 6.7% International sales were ₹ 7,604 million, year-on-year decline of 3.8% o o  Earnings before

₹ 7,604 million

of 5.7% India sales were ₹ 17,815 million, year-on-year decline of 6.7% International sales were ₹ 7,604 million, year-on-year decline of 3.8% o o  Earnings before Interest, Tax, Depreciation and Amortizat

3.8%

on, year-on-year decline of 6.7% International sales were ₹ 7,604 million, year-on-year decline of 3.8% o o  Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 2,032 milli

₹ 2,032 million

cline of 3.8% o o  Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was ₹ 2,032 million, resulting in EBITDA margin of 7.9% vs. 21.7% in Q1FY21. EBITDA declined by 65.7% YoY  R&D expen

7.9%

st, Tax, Depreciation and Amortization (EBITDA) was ₹ 2,032 million, resulting in EBITDA margin of 7.9% vs. 21.7% in Q1FY21. EBITDA declined by 65.7% YoY  R&D expenses for the quarter was ₹ 1,320 milli

21.7%

Depreciation and Amortization (EBITDA) was ₹ 2,032 million, resulting in EBITDA margin of 7.9% vs. 21.7% in Q1FY21. EBITDA declined by 65.7% YoY  R&D expenses for the quarter was ₹ 1,320 million, or 5.1

65.7%

A) was ₹ 2,032 million, resulting in EBITDA margin of 7.9% vs. 21.7% in Q1FY21. EBITDA declined by 65.7% YoY  R&D expenses for the quarter was ₹ 1,320 million, or 5.1% of total revenue from operations

₹ 1,320 million

argin of 7.9% vs. 21.7% in Q1FY21. EBITDA declined by 65.7% YoY  R&D expenses for the quarter was ₹ 1,320 million, or 5.1% of total revenue from operations compared to ₹ 1,183 million in Q1FY22 at 4.3% of total

Details of the conference call are as under

1

Dial in Details

1

Dial in Details

India : +91 22 6280 1149 / +91 22 7115 8050 International Toll Free USA UK Singapore Hong Kong : 1 866 746 2133 : 0 808 101 1573 : 800 101 2045 : 800 964 448 Express Join with Diamond Pass https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=6573919&linkS ecurityString=1d6ca845e8 You are requested to dial in 10 mins ahead of the scheduled start time. A transcript of this conference call will also be available on our website www.alkemlabs.com About Alkem Laboratories Ltd. Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in